Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy

Helicobacter

Volumn 18, Issue 4, 2013, Pages 270-273

  Prasertpetmanee, Sanchai ^a   Mahachai, Varocha ^b,c   Vilaichone, Ratha korn ^a,c  

^a THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

^b Bangkok Medical Center   (Thailand)

^c National Gastric Cancer and Helicobacter pylori Research Center   (Thailand)

Author keywords

Amoxicillin; Clarithromycin; Helicobacter pylori; Improved triple therapy; Nonulcer dyspepsia; Proton pump inhibitors; Thailand

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE; METRONIDAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERIUM CULTURE; BITTER TASTE; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEMALE; FLOODING; GENOTYPE; HEADACHE; HEART PALPITATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STANDARD; THAILAND; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; THAILAND; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 84879446297     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12041     Document Type: Article

References (19)

1. Mahachai V, Vilaichone RK. Current status of Helicobacter pylori infection in Thailand. Helicobacter Res 2011;15:38-44.
2. Vilaichone RK, Mahachai V, Graham DY. Helicobacter pylori: diagnosis and management. Gastroenterol Clin North Am 2006;35:229-47.
3. Vilaichone RK, Mahachai V. Current management of Helicobacter pylori infection. J Med Assoc Thai 2001;84:S32-8.
4. Mahachai V, Sirimontaporn N, Tumwasorn S, et al. Sequential therapy in clarithromycin sensitive and resistant H. pylori based on PCR molecular test. J Gastroenterol Hepatol 2011;26:825-8.
5. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
6. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
7. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am 2010;39:465-80.
8. Sugimoto M, Graham DY. High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication. Nat Clin Pract Gastroenterol Hepatol 2009;6:138-9.
9. McNicholl AG, Linares PM, Nyssen OP, et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012;36:414-25.
10. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69:158-68.
11. Yamada S, Onda M, Kato S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 2001;36:669-72.
12. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
13. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
14. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009;7:145-8.
15. Villoria A, Garcia P, Calvet X, et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008;28:868-77.
16. Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012;36:627-34.
17. Shirai N, Sugimoto M, Kodaira C, et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007;63:743-9.
18. Graham DY, Javed SU, Keihanian S, et al. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol 2010;45:816-20.
19. Attumi TA, Graham DY. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol 2012;27:59-61.